2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
808
Precursor Cell Lymphoblastic Leukemia-Lymphoma
171
Recurrence
141
Neoplasms, Plasma Cell
111
Lymphoma
93
Leukemia
91
Neoplasms
81
Burkitt Lymphoma
57
Vomiting
51
Lymphoma, Non-Hodgkin
50
Immunoglobulin Light-chain Amyloidosis
50
Lymphoma, Large B-Cell, Diffuse
44
Nausea
38
Lymphoma, Mantle-Cell
38
Prostatic Neoplasms
31
Lymphoma, Follicular
30
Hodgkin Disease
29
Waldenstrom Macroglobulinemia
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
27
Neoplasm Metastasis
26
Leukemia, Lymphocytic, Chronic, B-Cell
26
Carcinoma, Non-Small-Cell Lung
26
Leukemia, Myeloid, Acute
25
Breast Neoplasms
25
Lung Neoplasms
23
Amyloidosis
21
Leukemia, Biphenotypic, Acute
18
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, Extranodal NK-T-Cell
16
Smoldering Multiple Myeloma
15
Interventions
enzalutamide
20
Abiraterone Acetate
11
Prednisone
7
Docetaxel
7
radium Ra 223 dichloride
6
darolutamide
5
abiraterone
5
apalutamide
3
olaparib
2
niraparib
2
cabazitaxel
2
atezolizumab
2
Pluvicto
2
Nivolumab
2
zimberelimab
1
xentuzumab
1
tasquinimod
1
sacituzumab govitecan
1
sabizabulin
1
quemliclustat
1
pembrolizumab
1
ipatasertib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
TVB-2640
1
Standard of Care
1
Rosuvastatin Calcium
1
Radium-223
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
Dexamethasone
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled